Date of Award




Document Type


Degree Name

Doctor of Philosophy (PhD)


Department of Epidemiology and Biostatistics



Content Description

1 online resource (viii, 149 pages) : illustrations (some color), maps.

Dissertation/Thesis Chair

Lou C Smith

Committee Members

Alvaro Carrascal, Kristi McClamroch, A. Greg DiReinzo, Colleen Flanigan


Hepatitis C Virus, Incidence, Markov modeling, Morbidity, Mortality, Prevalence, Hepatitis C, Hepatitis C virus

Subject Categories



Hepatitis C virus (HCV) infection is estimated to be the most common chronic blood-borne infection in the United States (US). Annual incidence of HCV in the US peaked in the late 1980's, declined steadily through the 1990's and has plateaued since 2003 with approximately 18,000 new cases in 2008. The morbidity and mortality associated with HCV is expected to rise until at least 2015. Due to the high rate of asymptomatic cases, inherent limitations with target screening recommendations, limitations with screening technologies and scarce resources for surveillance nationwide, quantification of the burden is difficult. US estimates of disease burden have been conducted; however, the burden in New York State (NYS) is currently unknown. Quantification at the state-level will help inform health policy and planning decisions regarding counseling, screening, medical management and resource allocation. Thus, the purpose of this research is to estimate in NYS: 1) the prevalence of both HCV antibody (anti-HCV) positive and chronically infected individuals, 2) the past incidence of infections, and 3) the current and future morbidity and mortality associated with HCV.

Included in

Epidemiology Commons